EVIDENCE, NOT ANECDOTE

Explore the science behind
peptide research.

Search mechanisms, development status, studied protocols, safety findings and primary sources—clearly separated by level of evidence.

Neurocognitive · ImmuneReviewed September 2026

Selank

TP-7 · Tuftsin analog

Limited humanNot FDA approved

A synthetic tuftsin analog with small regional studies and limited internationally replicated clinical evidence.

01

Mechanism

Proposed anxiolytic and immunomodulatory signaling

02

Protocol studied in research

Study design shown in plain language. This is not a personal dosing recommendation.

No validated human protocolEvidence landscape
PubMed literature
Dose studiedNot established
RouteNot established
FrequencyNot established
DurationNot established
Study population

Human evidence is absent, limited or not confirmatory

Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.

03

Community-Reported Research Schedules

Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.

Community quick referenceStandardized schedule context
Reported range250–750 mcg/day
FrequencyDaily
RouteIntranasal or subcutaneous
Reported half-life~5 minutes
Cycle context10–14 days commonly reported
Cross-reference reviewed September 2026Community-reported · not clinical validation
Research context or phaseAmount per administrationSchedule totalFrequencyTimingAdministrationEvidence level
Common intranasal range250–750 mcg250–750 mcg/dayOnce or divided dailyDivided across waking hoursIntranasalCommunity-reported

Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.

04

Example Reconstitution Protocol

A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.

Calculation example onlyIllustrative vial math
Example vial10 mg (hypothetical)
Example diluent volume2 mL (illustrative volume)
Resulting concentration5 mg/mL
Illustrative amount500 mcg
Calculated volume0.1 mL
U-100 scale equivalent10 units
Formulaconcentration = vial amount ÷ diluent volumevolume = illustrative amount ÷ concentrationU-100 units = mL × 100

Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.

05

Cycle & Supplies Planning

Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.

Supply total not calculated10 mg (hypothetical) · 2 mL (illustrative volume)

No single, consistently reported subcutaneous amount-and-frequency pair is available for a responsible automatic supply calculation.

Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.

06

Safety signal

Available evidence is insufficient to define reliable efficacy, product quality, interactions or long-term safety.

Research context matters.

Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.

OUR METHOD

Every claim has a place
on the evidence ladder.

01

Primary sources first

Peer-reviewed trials, FDA materials, registries and original pharmacology—not social media summaries.

02

Evidence stays separated

FDA-approved, clinical-stage, early human and preclinical findings are never presented as equivalent.

03

Protocols stay in context

Route, frequency, duration and population appear together, so a study is not mistaken for personal guidance.